Bayer HealthCare AG Spin-Out, Actimis, Complete $6 Million Financing

Actimis Pharmaceuticals, a startup company dedicated to developing and commercializing small molecule therapeutics for respiratory and inflammatory diseases, today announced a $6 million private placement of its Series A stock. The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co. Venture Partners of New York. Bayer HealthCare AG has assigned the rights to five preclinical research programs to Actimis, including two advanced programs with highly optimized lead candidates and three additional research-stage programs.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-28-2005/0003491051&EDATE=)